Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2359-2365

  Sobol, Robert E ^a   Shawler, Daniel L ^a   Carson, Colette ^a   Van Beveren, Charles ^a   Mercola, Dan ^a   Fakhrai, Habib ^a   Garrett, Mia A ^a   Barone, Robert ^b   Goldfarb, Paul ^b   Bartholomew, Richard M ^c   Brostoff, Steven ^c   Carlo, Dennis J ^c   Royston, Ivor ^a   Gold, Daniel P ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b SHARP HEALTHCARE   (United States)

^c Orchestra Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TUMOR CELL VACCINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FATIGUE; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

CANCER VACCINES; CELL TRANSPLANTATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FIBROBLASTS; GENE THERAPY; GENETIC ENGINEERING; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032851163     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hoover, H. C., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J., Muenz, L. R., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol., 1: 390-399, 1993.
2. Herlyn, D., Linnenbach, A., Koprowski, H., and Herlyn, M. Epitope-and antigen-specific cancer vaccines. Int. Rev. Immunol., 7: 245-257, 1991.
3. Herlyn, D., Harris, D., Zaloudik, J., Sperlagh, M., Maruyama, H., Jacob, L., Kieny, M-P., Scheck, S., Somasundaram, R., Hart, E., Ertl, H., and Mastrangelo, M. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother., 15: 303-311, 1994.
4. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell, 60: 387-403, 1990.
5. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin-2 gene transfer into tumor cells abrogates tumor-igenicity and induces protective immunity. J. Exp. Med., 772: 1217-1223, 1990.
6. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E. L., Taniyama, T., and Sakata, T. A. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 86: 9456-9460, 1989.
7. Tepper, R. I., Pattengale, P. K., and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57: 503-512, 1989.
8. Fakhrai, H., Shawler, D. L., Gjerset, R., Naviaux, R. K., Koziol, J., Royston, I., and Sobol, R. E. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther., 6: 591-601, 1995.
9. Fakhrai, H., Shawler, D. L., Van Beveren, C., Lin, H., Dorigo, O., Solomon, M. J., Gjerset, R. A., Smith, L., Bartholomew, R. M., Boggiano, C. A., Gold, D. P., and Sobol, R. E. Construction and characterization of retroviral vectors for interleukin-2 gene therapy. J. Immunother., 20: 437-448, 1997.
10. Ostrove, J. M. Safety testing programs for gene therapy viral vectors. Cancer Gene Ther., 1: 125-131, 1994.
11. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol., 126: 1614-1619, 1981.
12. Shawler, D. L., McCallister, T. J., Sobol, R. E., and Dillman, R. O. Serologic and cellular assays to monitor therapy with murine monoclonal antibodies. J. Clin. Lab. Anal., 1: 184-190, 1987.
13. Crowley, N. J., Slingluff, C. L., Jr., Darrow, T. L., and Seigler, H. F. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res., 50: 492-498, 1990.
14. Crowley, N. J., Darrow, T. L., Quinn-Allen, M. A., and Seigler, H. F. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J. Immunol., 146: 1692-1699, 1991.
15. Pandolfi, F., Boyle, L. A., Trentin, L., Kurnick, J. T., Isselbacher, K. J., and Gattoni-Celli, S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res., 51: 3164-3170, 1991.
16. Chen, Q., Smith, M., Nguyen, T., Maher, D. W., and Hersey, P. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells. Cancer Immunol. Immunother., 38: 385-393, 1994.
17. Finn, O. J. Tumor-rejection antigens recognized by T lymphocytes. Curr. Opin. Immunol., 5: 701-708, 1993.
18. De Plaen, E., Arden, K., Traversari, C., Gaforio, J. T., Szikora, J. P., De Smet, C., Brasseur, F., van der Bruggen, P., Lethe, B., and Lurquin, C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics, 40: 360-369, 1994.
19. Sobol, R. E., Fakhrai, H., Shawler, D. L., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T. A., and Royston, I. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther., 2: 164-167, 1995.
20. Belli, F., Arienti, F., Sule-Suso, J., Clemente, C., Mascheroni, L., Cattelan, A., Santantonio, C., Gallino, G. F., Melani, C., Rao, S., Colombo, M. P., Maio, M., Cascinelli, N., Parmiani, G., and Sanatonio, C. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (published erratum appears in Cancer Immunol. Immunother., 45: 119, 1997). Cancer Immunol. Immunother., 44: 197-203, 1997.
21. Nabel, G. J., Nabel, E. G., Yang, Z-Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA, 90: 11307-11311, 1993.
22. Veelken, H., Mackensen, A., Lahn, M., Kohler, G., Becker, D., Franke, B., Brennscheidt, U., Kulmburg, P., Rosenthal, F. M., Keller, H., Hasse, J., Schultze-Seemann, W., Farthmann, E. H., Mertelsmann, R., and Lindemann, A. A Phase-I clinical study of autologous tumor cells plus interleukin-2 gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer, 70: 269-277, 1997.